Pomegra
Now I have all the data needed. Writing the article with accurate figures from the research.
- TRIMTECH raised a $14M seed extension, bringing total seed capital to $47M (approximately £35.6M), announced June 23, 2026.
- Johnson & Johnson Innovation – JJDC and BGF co-led the extension; JJDC and Pfizer Ventures and Eli Lilly had already backed the initial round.
- The Cambridge biotech is developing TRIMTAC and TRIMGLUE degraders targeting toxic protein aggregates in Alzheimer's and Huntington's disease.
Lead
TRIMTECH Therapeutics, a Cambridge-based biotechnology company focused on neurodegenerative disease, announced on June 23, 2026 a $14 million extension to its seed financing, lifting the total raised to $47 million. Johnson & Johnson Innovation – JJDC, Inc. and BGF co-led the extension round, with JJDC and BGF representatives joining TRIMTECH's board as non-executive directors.What Happened
The fresh $14 million follows a $31 million initial seed close completed in March 2025, which attracted Cambridge Innovation Capital, SV Health Investors' Dementia Discovery Fund, M Ventures, Pfizer Ventures, Eli Lilly, MP Healthcare Venture Management, Cambridge Enterprise Ventures, and Start Codon. The extension adds two strategically significant corporate investors, deepening a pharma-industry endorsement of TRIMTECH's targeted protein degradation platform.
The participation of three major pharmaceutical corporate venture arms — JJDC, Pfizer Ventures, and Eli Lilly — alongside specialist dementia funds reflects substantial conviction in the company's science at an early stage.
Technology Platform
Founded in 2023 as a spin-out from the MRC Laboratory of Molecular Biology and the UK Dementia Research Institute at the University of Cambridge, TRIMTECH has built its pipeline around TRIM21, a naturally occurring E3-ubiquitin ligase that the immune system normally deploys to destroy antibody-coated viruses inside cells. The company has repurposed this mechanism into two therapeutic degrader platforms:
- TRIMTAC degraders — aggregate-selective molecules engineered to penetrate the central nervous system and destroy toxic protein clumps
- TRIMGLUE degraders — molecular glue-based compounds that redirect protein degradation machinery
Both platforms are designed to eliminate the oligomeric and aggregated forms of disease-associated proteins — such as amyloid and tau in Alzheimer's, or mutant huntingtin in Huntington's disease — while leaving healthy monomeric protein intact to support normal cellular function. The selectivity is the key differentiator from earlier-generation approaches that broad-targeted entire protein families.
Strategic Context
The seed extension places TRIMTECH among a cohort of precision protein degradation companies that have attracted outsized early-stage capital on the premise that traditional small molecule and antibody approaches have failed to adequately address neurodegeneration's root cause: the accumulation and seeding of misfolded proteins across neural tissue.
J&J Innovation's entry through JJDC is notable. Johnson & Johnson has sustained significant investment in neuroscience — spanning Alzheimer's immunotherapy through its Janssen unit — and TRIMTECH's CNS-penetrant degraders address a mechanistic gap that antibody-based programs cannot easily fill. BGF, one of the UK's largest growth-capital investors, adds domestic institutional weight to a predominantly scientific investor base.CEO Nicki Thompson, who previously co-founded targeted protein degradation company Amphista Therapeutics, brings direct precedent in translating academic degrader science into clinical-stage programs. Thompson noted the funding enables the company to advance its CNS-penetrant degrader portfolio across both platforms.
Outlook
With $47 million in seed capital and board-level engagement from JJDC and BGF, TRIMTECH is positioned to move its TRIMTAC and TRIMGLUE programs through preclinical development toward IND-enabling studies. The company's Cambridge location, academic origins, and backing from multiple pharma corporate venture arms give it a credible path toward partnership discussions and, ultimately, clinical trials in Alzheimer's and Huntington's disease — two areas where therapeutic need remains acutely unmet.
